Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)
- Resource Type
- Article
- Source
- In
Gynecologic Oncology July 2018 150(1):9-13 - Subject
- Language
- ISSN
- 0090-8258